Trulieve Cannabis earnings and DEA registration shift the conversation
Trulieve Cannabis (TRLV) just paired a return to quarterly profitability with fresh DEA registrations for its medical marijuana dispensaries, reshaping how investors may think about both its earnings profile and regulatory footing.
Trulieve Cannabis has seen momentum build over 2026, with a 1-year total shareholder return of 59.8% and a year to date share price return of 27.47% despite a softer 7 day share price move. That upswing has coincided with the DEA registration news and the third quarter swing back into quarterly profit.
Scan for other cannabis and healthcare operators showing similar earnings and regulatory momentum by checking the hand picked 36 healthcare AI stocks that could sit alongside Trulieve Cannabis in a watchlist.
Trulieve Cannabis now trades at a steep discount to both analyst targets and intrinsic value estimates after this DEA backed rally. Is that a mispricing, or is the market putting a lid on regulatory and earnings risk?
Most Popular Narrative: 39% Undervalued
On the analyst consensus Narrative on Simply Wall St, Trulieve Cannabis screens as undervalued, with a fair value of $18.18 against the recent $11.09 close. This puts the DEA registration news into a much bigger earnings and tax story.
Federal reclassification of medical marijuana to Schedule III, along with the ability to register with the DEA and deduct ordinary expenses, is expected to reduce the impact of 280E and could free up more cash to support earnings and operating margins over time.
See why 8 investors see Trulieve Cannabis as 39% undervalued.
Result: Fair Value of $18.18 (UNDERVALUED)
Still, the bullish Trulieve Cannabis narrative depends heavily on smooth federal rescheduling and tax outcomes, while pricing pressure and softer consumer spending could undercut those expectations.
Find out about the key risks to this Trulieve Cannabis narrative.
Next Steps
Mixed signals on Trulieve Cannabis so far, so do not let the headline sentiment make the decision for you when the data is this split. Take a few minutes to weigh both sides of the story by reviewing the 3 key rewards and 1 important warning sign.
Looking for more Trulieve Cannabis style ideas?
If you only stop at Trulieve Cannabis, you could miss opportunities that better match your risk tolerance, time horizon, and income goals across the market.
- Target potential mispricings by scanning a curated set of value candidates through the 35 high quality undervalued stocks.
- Build resilience into your portfolio by focusing on companies with strong finances using the list of solid balance sheet and fundamentals (24 results).
- Hunt for lesser known opportunities with quality fundamentals through the 20 high quality undiscovered gems.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com